Home › Companies › CNTB

Connect Biopharma

Market cap $37.3M 64.5M shares (10-Q, Oct 30, 2026) × $0.579 close Nov 17, 2026

Most recent annual filing: 2026-03-31

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Rademikibart atopic dermatitis China decision2H 2026Rademikibart atopic dermatitis China decision, 2H 2026, material
  2. Rademikibart FDA feedbackDec 2026Rademikibart FDA feedback, Dec 2026, notable
  3. COPD Phase 3 corporate update1Q 2027COPD Phase 3 corporate update, 1Q 2027, routine
  4. Nasdaq listing updateMay 11, 2027Nasdaq listing update, May 11, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (1)

Capital (as filed)

Cash
$16.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$3.0M Sep 30, 2026
Operating cash flow
−$12.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$19.5M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Connect Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Connect Biopharma (CNTB) - Scientific Deep Dive for Rademikibart and Pipeline Products Differentiated mechanism and real acute-exacerbation white space, but the entire equity hinges on one funded-but-binary mid-2026 Seabreeze readout in a novel endpoint, against subgroup-heavy supporting data and a China-structure/Phase-3-dilution overhang.
  2. Speculative buy speculative UPDATE: Connect Biopharma (CNTB) - The Clock Is Set, The Cushion Is Gone Readout now has a firm month (September), both trials finished enrollment at plan with no futility stop, and Simcere milestone cash is flowing — asymmetry intact on a validated target with a differentiated mechanism, but sized only as a starter given the thinned cash cushion.
  3. Watch UPDATE: Connect Biopharma (CNTB) - The Trial Failed. The Drug Might Not Have. Asthma primary endpoint missed (p=0.153, 8 total events) while the Week-1 FEV₁ secondary hit, leaving a split result that forces a dilutive raise from a broken tape without the clean re-rating needed to finance Phase 3.
  4. Watch UPDATE: Connect Biopharma (CNTB) - The Mirror Image COPD hit the clinical-outcome primary (81% fewer treatment failures, p=0.0122) but missed Day-7 FEV₁, giving two trials pointing the same direction on treatment failure but never both endpoints in the same disease; the balance sheet dilution event remains the binding constraint and the upgrade trigger.
  5. Avoid UPDATE: Connect Biopharma (CNTB) - The Going-Concern Flag Going-concern warning, Nasdaq deficiency notice, and ATM drip sales instead of a priced institutional raise mean the dilution path has gone the bad way — owning the stock now means financing the company on its worst terms despite two trials pointing the same direction on treatment failure.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (19)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 12, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)